A Phase 1/2 interventional study of Isatuximab SAR650984 and Acetaminophen (paracetamol) or equivalent in Immune System Disorder, sponsored by Sanofi. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Objectives:
Secondary Objectives:
The study had a screening period of up to 28 days, a treatment period of up to 12 weeks, a site visit FUP of up to 26 weeks, and an extended follow-up (FUP) until study cut-off.
The study duration involved site visit per participant (i.e., screening, treatment, site visit FUP was approximately 42 weeks.
The study duration included extended FUP per participant was approximately 97.7 weeks (depending on when the participant was enrolled).
428 studies on the registry are indexed under Immune System Diseases; 86 are open to participants now.
This study's enrollment of 23 is below the median of 66 across 317 interventional studies indexed under Immune System Diseases.
Browse Immune System Diseases studies →Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Participants in Cohort A: active candidates on the kidney waitlist with living donor.
For Participants in Cohort B: active candidates on the kidney waitlist with no living donor cleared for donation.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with calculated panel reactive antibodies (cPRA) \>=99.90% (indicating active candidates on kidney transplant waitlist) received isatuximab 10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, once weekly (QW) for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1) and then every 2 weeks (Q2W) for subsequent treatment cycles (each cycle of 28 days) until unacceptable adverse events (AEs) or participant's decision to stop the treatment (maximum treatment duration: 13 weeks).
Drug: Isatuximab SAR650984 · Drug: Acetaminophen (paracetamol) or equivalent · Drug: Ranitidine or equivalent · Drug: Diphenhydramine or equivalent · Drug: Methylprednisolone or equivalent · Drug: Montelukast or equivalent
Participants with cPRA between 80.00% to 99.89% (indicating active candidates on kidney transplant waitlist with no living donor cleared for donation) received isatuximab 10 mg/kg, IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1) and then Q2W for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs or participant's decision to stop the treatment (maximum treatment duration: 13 weeks).
Drug: Isatuximab SAR650984 · Drug: Acetaminophen (paracetamol) or equivalent · Drug: Ranitidine or equivalent · Drug: Diphenhydramine or equivalent · Drug: Methylprednisolone or equivalent · Drug: Montelukast or equivalent
Pharmaceutical form: Solution for infusion Route of administration: Intravenous
Also known as: Sarclisa
Pharmaceutical form: Tablets Route of administration: Oral
Pharmaceutical form: Solution Route of administration: Intravenous
Pharmaceutical form: Solution Route of administration: Intravenous
Pharmaceutical form: Solution Route of administration: Intravenous
Pharmaceutical form: Tablets Route of administration: Oral
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study drug until study cut-off date).
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Number of Participants With Hematological Abnormalities
Abnormal hematological parameters assessed were anemia, platelet count decreased, neutrophil count decreased, lymphocyte count decreased and monocytes. The hematological abnormality grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Monocytes were assessed as per potentially clinically significant abnormality (PCSA) criteria defined as: greater than (\>) 0.7\*10\^9/L.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Number of Participants With Renal Function Abnormalities
Abnormal renal parameters assessed were creatinine increased and estimated Glomerular Filtration Rate (eGFR). The renal function abnormality grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. eGFR was assessed as per PCSA criteria: 60 (less than equal to) \<= to less than (\<) 90 milliliter/minute/1.73 meter square (mL/min/1.73m\^2) (Mild), 30\<= to \<60 mL/min/1.73m\^2 (Moderate), 15\<=to \<30 mL/min/1.73m\^2 (Severe), \<15 mL/min/1.73m\^2 (End Stage Renal Disease).
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Number of Participants With Abnormal Electrolytes Parameters
Abnormal electrolyte parameters assessed were hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, blood bicarbonate decreased, hypermagnesemia, hypomagnesemia and chloride. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Chloride was estimated as per PCSA criteria: \<80 millimoles per liter (mmol/L) and \>115 mmol/L.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Number of Participants With Abnormal Metabolism Parameters
Abnormal metabolism parameters assessed were hypoglycemia, hypoalbuminemia and glycated Hemoglobin (HbA1c). The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. HbA1c was estimated as per PCSA criteria: \>8%.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Number of Participants With Liver Function Abnormalities
Abnormal liver function parameters assessed were Alanine aminotransferase (ALT) increased, Aspartate aminotransferase (AST) increased, Alkaline phosphatase (ALP) increased, and Total bilirubin (TB) increased. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Percentage of Participants With Response
Response was defined as the percentage of participants meeting at least one of the predefined desensitization efficacy criteria as measured by single antigen bead (SAB) assay as follows: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer (\>=75% reduction from Baseline) to achieve target cPRA; elimination of \>=1 human leukocyte antigen (HLA) antibody (i.e., mean fluorescence intensity \[MFI\] reduced to \<2000) as measured by a SAB assay, for antibodies with Baseline MFI \>=3000.
Time frame: From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)
Pharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
Time frame: At End of infusion on Cycle 1 Day 1
PK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab
Cmax was defined as the maximum concentration observed after the first administration calculated using the noncompartmental analysis after the intravenous infusion of isatuximab.
Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
PK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab
Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
PK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab
Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification calculated using non-compartmental analysis after the first infusion of isatuximab.
Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
PK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab
Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
PK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab
Ctrough was the plasma concentration of isatuximab observed just before (pre-dose) treatment administration.
Time frame: Cycle 2 Day 1
PK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab
AUC0-168 hours was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated using trapezoidal method after first infusion of isatuximab.
Time frame: At Start of infusion (SOI), End of infusion (EOI), EOI+4H (initial protocol) EOI+1H (amended protocol), 72H and 168H on Day 1 of Cycle 1
Number of Participants With Anti-drug Antibodies (ADA) Against Isatuximab
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Duration of Response (DOR)
Duration of response (DOR) was defined as time (in weeks) from laboratory sample collection date used in determining a participant to be a responder (defined as participants meeting at least one of the predefined desensitization efficacy criteria: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer \[\>=75% reduction from Baseline\] to achieve target cPRA; elimination of \>=1 anti-HLA antibody i.e. MFI reduced to \<2000 as measured by a SAB assay, for antibodies with Baseline MFI \>=3000) up to the laboratory sample collection date when participant was confirmed as no longer meeting any response criterion (i.e., non-responder) or the date of death due to any cause, whichever occurs first. DOR was analyzed using Kaplan-Meier method.
Time frame: From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)
Number of Participants Achieving Target cPRA
Target calculated panel reactive antibodies (cPRA) was defined as the reduction of cPRA required to achieve at least 100% increase of likelihood of compatible donor (LCD). Number of participants who achieved target cPRA was assessed using the Organ Procurement and Transplantation Network (OPTN) calculator during the specified timepoint were reported in this outcome measure. Participants who retained their target cPRA values were censored at the date of the last available laboratory assessment achieving their target cPRA.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Duration for Achieving Target cPRA
Duration of achieving target cPRA was defined as the time (in weeks) from laboratory sample collection date of achieving target cPRA (defined as the reduction of cPRA required to achieve at least 100% increase of LCD) the first time up to the laboratory sample collection date when no longer achieving target cPRA calculated using OPTN calculator or the date of death due to any cause, whichever occurs first. The duration of achieving target cPRA was assessed using the Kaplan-Meier method.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Number of Participants With Anti-Human Leukocyte Antigen (HLA)-Antibody Reduction
Number of participants with anti-HLA-antibody (Baseline MFI \>=3000) reduced to \<2000 as measured using a SAB assay per central laboratory assessment was reported in this outcome measure. Participants were categorized in various categories of number of antibodies which were reduced as: none, 1-5, \>5-10, \>10-15, and \>15. If multiple visits had the same number of total anti-HLA antibody reduction, the last visit data was summarized.
Time frame: From first dose of study drug until end of follow-up period (maximum duration: up to 39.1 weeks)
Time to First Transplant Offer
Time to first transplant offer was defined as time (in days) from date of first study treatment dose up to date of first kidney transplant offer. Data on transplant status were collected and followed up until study cut-off date.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Time to Transplant
Time to transplant was defined as time (in days) from date of first study treatment dose up to date of kidney transplant. Data on transplant status were collected and followed up until study cut-off date.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Number of Kidney Transplant Offers
Number of kidney transplants offers received for each participant was reported in the outcome measure. Data on transplant offers were collected and followed up until study cut-off date.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Time to First Antibody Mediated Rejection (AMR) Episode
Time to first AMR was defined as time from date of first study treatment dose up to date of biopsy with first AMR (defined as the graft rejection due to generation of antibodies against the graft). Transplanted participants without any AMR were censored at the participant's last assessment or contact date collected in the study or at the analysis cut-off date, whichever was earlier.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Percentage of Participants Who Experienced Any Antibody Mediated Rejection (AMR)
Antibody mediated rejection was defined as the graft rejection due to generation of antibodies against the graft. The number of participants with AMR field checked as 'yes' based on the graft rejection biopsy in the electronic case report form was considered.
Time frame: From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks)
Number of Participants With Graft Survival at 6 Months Post-Transplant
Number of participants with graft survival status as functioning at 6-months post-transplant was reported in this outcome measure.
Time frame: At 6 Months post-transplant
Study was conducted at 6 active sites in 2 countries. A total of 23 participants were enrolled between 18 Jun 2020 and 02 Nov 2021 and received isatuximab monotherapy.
| Milestone | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Started | 12 | 11 |
| Completed | 12 | 10 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious adverse events (SAEs) were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study drug until study cut-off date).
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| TEAEs | 3 | 4 |
| TESAEs | 0 | 0 |
Abnormal hematological parameters assessed were anemia, platelet count decreased, neutrophil count decreased, lymphocyte count decreased and monocytes. The hematological abnormality grades were based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Monocytes were assessed as per potentially clinically significant abnormality (PCSA) criteria defined as: greater than (\>) 0.7\*10\^9/L.
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Anemia: Grade 1 | 6 | 8 |
| Anemia: Grade 2 | 3 | 2 |
| Anemia: Grade 3 | 0 | 0 |
| Anemia: Grade 4 | 0 | 0 |
| Platelet count decreased: Grade 1 | 2 | 6 |
| Platelet count decreased: Grade 2 | 0 | 0 |
| Platelet count decreased: Grade 3 | 0 | 0 |
| Platelet count decreased: Grade 4 | 0 | 0 |
| Neutrophil count decreased: Grade 1 | 0 | 0 |
| Neutrophil count decreased: Grade 2 | 0 | 0 |
| Neutrophil count decreased: Grade 3 | 0 | 0 |
| Neutrophil count decreased: Grade 4 | 0 | 0 |
| Lymphocyte count decreased: Grade 1 | 4 | 2 |
| Lymphocyte count decreased: Grade 2 | 1 | 1 |
| Lymphocyte count decreased: Grade 3 | 1 | 0 |
| Lymphocyte count decreased: Grade 4 | 0 | 0 |
| Monocytes (PCSA) > 0.7*10^9/L | 3 | 3 |
Abnormal renal parameters assessed were creatinine increased and estimated Glomerular Filtration Rate (eGFR). The renal function abnormality grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. eGFR was assessed as per PCSA criteria: 60 (less than equal to) \<= to less than (\<) 90 milliliter/minute/1.73 meter square (mL/min/1.73m\^2) (Mild), 30\<= to \<60 mL/min/1.73m\^2 (Moderate), 15\<=to \<30 mL/min/1.73m\^2 (Severe), \<15 mL/min/1.73m\^2 (End Stage Renal Disease).
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Creatinine increased: Grade 1 | 0 | 0 |
| Creatinine increased: Grade 2 | 0 | 0 |
| Creatinine increased: Grade 3 | 1 | 3 |
| Creatinine increased: Grade 4 | 11 | 8 |
| eGFR: 60<= - <90 mL/min/1.73m^2 | 0 | 0 |
| eGFR: 30<= - <60 mL/min/1.73m^2 | 0 | 0 |
| eGFR: 15<= - <30 mL/min/1.73m^2 | 0 | 0 |
| eGFR: <15 mL/min/1.73m^2 | 12 | 11 |
Abnormal electrolyte parameters assessed were hypernatremia, hyponatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, blood bicarbonate decreased, hypermagnesemia, hypomagnesemia and chloride. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Chloride was estimated as per PCSA criteria: \<80 millimoles per liter (mmol/L) and \>115 mmol/L.
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Hypernatremia: Grade 1 | 0 | 0 |
| Hypernatremia: Grade 2 | 0 | 0 |
| Hypernatremia: Grade 3 | 0 | 0 |
| Hypernatremia: Grade 4 | 0 | 0 |
| Hyponatremia: Grade 1 | 4 | 1 |
| Hyponatremia: Grade 2 | 0 | 0 |
| Hyponatremia: Grade 3 | 0 | 0 |
| Hyponatremia: Grade 4 | 0 | 0 |
| Hyperkalemia: Grade 1 | 2 | 6 |
| Hyperkalemia: Grade 2 | 3 | 1 |
| Hyperkalemia: Grade 3 | 1 | 2 |
| Hyperkalemia: Grade 4 | 0 | 0 |
| Hypokalemia: Grade 1 | 0 | 0 |
| Hypokalemia: Grade 2 | 0 | 0 |
| Hypokalemia: Grade 3 | 0 | 0 |
| Hypokalemia: Grade 4 | 1 | 0 |
| Hypercalcemia: Grade 1 | 0 | 1 |
| Hypercalcemia: Grade 2 | 1 | 0 |
| Hypercalcemia: Grade 3 | 0 | 0 |
| Hypercalcemia: Grade 4 | 0 | 0 |
| Hypocalcemia: Grade 1 | 6 | 5 |
| Hypocalcemia: Grade 2 | 0 | 2 |
| Hypocalcemia: Grade 3 | 0 | 0 |
| Hypocalcemia: Grade 4 | 0 | 0 |
| Hypermagnesemia: Grade 1 | 2 | 0 |
| Hypermagnesemia: Grade 2 | 0 | 0 |
| Hypermagnesemia: Grade 3 | 0 | 0 |
| Hypermagnesemia: Grade 4 | 0 | 0 |
| Hypomagnesemia: Grade 1 | 3 | 3 |
| Hypomagnesemia: Grade 2 | 0 | 0 |
| Hypomagnesemia: Grade 3 | 0 | 0 |
| Hypomagnesemia: Grade 4 | 0 | 0 |
| Chloride (PCSA): <80 mmol/L | 0 | 0 |
| Chloride (PCSA): >115 mmol/L | 0 | 0 |
Abnormal metabolism parameters assessed were hypoglycemia, hypoalbuminemia and glycated Hemoglobin (HbA1c). The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. HbA1c was estimated as per PCSA criteria: \>8%.
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Hypoglycemia: Grade 1 | 1 | 2 |
| Hypoglycemia: Grade 2 | 1 | 0 |
| Hypoglycemia: Grade 3 | 0 | 0 |
| Hypoglycemia: Grade 4 | 0 | 0 |
| Hypoalbuminemia: Grade 1 | 3 | 0 |
| Hypoalbuminemia: Grade 2 | 2 | 2 |
| Hypoalbuminemia: Grade 3 | 0 | 0 |
| Hypoalbuminemia: Grade 4 | 0 | 0 |
Abnormal liver function parameters assessed were Alanine aminotransferase (ALT) increased, Aspartate aminotransferase (AST) increased, Alkaline phosphatase (ALP) increased, and Total bilirubin (TB) increased. The abnormal grades were based on NCI-CTCAE, Version 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs.
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| ALT increased: Grade 1 | 1 | 1 |
| ALT increased: Grade 2 | 0 | 0 |
| ALT increased: Grade 3 | 0 | 0 |
| ALT increased: Grade 4 | 0 | 0 |
| AST increased: Grade 1 | 1 | 0 |
| AST increased: Grade 2 | 0 | 0 |
| AST increased: Grade 3 | 0 | 0 |
| AST increased: Grade 4 | 0 | 0 |
| ALP increased: Grade 1 | 3 | 2 |
| ALP increased: Grade 2 | 0 | 0 |
| ALP increased: Grade 3 | 0 | 0 |
| ALP increased: Grade 4 | 0 | 0 |
| TB increased: Grade 1 | 0 | 0 |
| TB increased: Grade 2 | 0 | 0 |
| TB increased: Grade 3 | 0 | 0 |
| TB increased: Grade 4 | 0 | 0 |
Response was defined as the percentage of participants meeting at least one of the predefined desensitization efficacy criteria as measured by single antigen bead (SAB) assay as follows: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer (\>=75% reduction from Baseline) to achieve target cPRA; elimination of \>=1 human leukocyte antigen (HLA) antibody (i.e., mean fluorescence intensity \[MFI\] reduced to \<2000) as measured by a SAB assay, for antibodies with Baseline MFI \>=3000.
| percentage of participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Percentage of Participants With Response | 83.3 (51.6 to 97.9) | 81.8 (48.2 to 97.7) |
Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.
| micrograms per milliliter (mcg/mL) | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Pharmacokinetics (PK) Parameters: Concentration Observed at the End of First Intravenous Infusion (Ceoi) of Isatuximab | 290 ± 128 | 270 ± 101 |
Cmax was defined as the maximum concentration observed after the first administration calculated using the noncompartmental analysis after the intravenous infusion of isatuximab.
| mcg/mL | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| PK Parameters: Maximum Concentration Observed (Cmax) After the First Infusion of Isatuximab | 295 ± 128 | 285 ± 94.0 |
Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
| hours | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| PK Parameters: Time Taken to Reach Cmax (Tmax) After the First Infusion of Isatuximab | 3.67 (2.00 to 6.03) | 3.40 (2.25 to 4.63) |
Clast was defined as the last concentration of isatuximab observed above the lower limit of quantification calculated using non-compartmental analysis after the first infusion of isatuximab.
| mcg/mL | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| PK Parameters: Last Concentration Observed Above the Lower Limit of Quantification (Clast) After the First Infusion of Isatuximab | 104 ± 41.7 | 76.3 ± 21.3 |
Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of isatuximab.
| hours | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| PK Parameters: Time of Clast (Tlast) After First Infusion of Isatuximab | 166.00 (49.60 to 169.00) | 167.00 (78.80 to 168.00) |
Ctrough was the plasma concentration of isatuximab observed just before (pre-dose) treatment administration.
| mcg/mL | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| PK Parameters: Trough Plasma Concentrations (Ctrough) of Isatuximab | 308 ± 79.4 | 246 ± 60.6 |
AUC0-168 hours was defined as the area under the plasma concentration versus time curve from time 0 to 168 hours post dose calculated using trapezoidal method after first infusion of isatuximab.
| micrograms*hours/milliliter (mcg*h/mL) | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| PK Parameters: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours Over the Dosing Interval (AUC0-168 Hours) After First Infusion of Isatuximab | 29400 ± 7400 | 20000 ± 5240 |
ADA responses were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA.
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Treatment-induced ADA | 0 | 0 |
| Treatment boosted ADA | 0 | 0 |
Duration of response (DOR) was defined as time (in weeks) from laboratory sample collection date used in determining a participant to be a responder (defined as participants meeting at least one of the predefined desensitization efficacy criteria: reduction in cPRA resulting in at least 100% increase of likelihood of finding a compatible donor; reduction in antibody titer \[\>=75% reduction from Baseline\] to achieve target cPRA; elimination of \>=1 anti-HLA antibody i.e. MFI reduced to \<2000 as measured by a SAB assay, for antibodies with Baseline MFI \>=3000) up to the laboratory sample collection date when participant was confirmed as no longer meeting any response criterion (i.e., non-responder) or the date of death due to any cause, whichever occurs first. DOR was analyzed using Kaplan-Meier method.
| weeks | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Duration of Response (DOR) | NA (4.857 to NA) | NA (4.143 to NA) |
Target calculated panel reactive antibodies (cPRA) was defined as the reduction of cPRA required to achieve at least 100% increase of likelihood of compatible donor (LCD). Number of participants who achieved target cPRA was assessed using the Organ Procurement and Transplantation Network (OPTN) calculator during the specified timepoint were reported in this outcome measure. Participants who retained their target cPRA values were censored at the date of the last available laboratory assessment achieving their target cPRA.
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Number of Participants Achieving Target cPRA | 4 | 2 |
Duration of achieving target cPRA was defined as the time (in weeks) from laboratory sample collection date of achieving target cPRA (defined as the reduction of cPRA required to achieve at least 100% increase of LCD) the first time up to the laboratory sample collection date when no longer achieving target cPRA calculated using OPTN calculator or the date of death due to any cause, whichever occurs first. The duration of achieving target cPRA was assessed using the Kaplan-Meier method.
| weeks | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Duration for Achieving Target cPRA | NA (3.429 to NA) | 7.29 (NA to NA) |
Number of participants with anti-HLA-antibody (Baseline MFI \>=3000) reduced to \<2000 as measured using a SAB assay per central laboratory assessment was reported in this outcome measure. Participants were categorized in various categories of number of antibodies which were reduced as: none, 1-5, \>5-10, \>10-15, and \>15. If multiple visits had the same number of total anti-HLA antibody reduction, the last visit data was summarized.
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| None | 2 | 2 |
| 1-5 antibodies | 4 | 4 |
| >5-10 antibodies | 4 | 4 |
| >10-15 antibodies | 1 | 0 |
| >15 antibodies | 1 | 1 |
Time to first transplant offer was defined as time (in days) from date of first study treatment dose up to date of first kidney transplant offer. Data on transplant status were collected and followed up until study cut-off date.
| days | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Time to First Transplant Offer | 373 (248 to 517) | 156 (117 to 402) |
Time to transplant was defined as time (in days) from date of first study treatment dose up to date of kidney transplant. Data on transplant status were collected and followed up until study cut-off date.
| days | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Time to Transplant | 445 (373 to 517) | 259.5 (117 to 402) |
Number of kidney transplants offers received for each participant was reported in the outcome measure. Data on transplant offers were collected and followed up until study cut-off date.
| transplant offers | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Number of Kidney Transplant Offers | 3 | 3 |
Time to first AMR was defined as time from date of first study treatment dose up to date of biopsy with first AMR (defined as the graft rejection due to generation of antibodies against the graft). Transplanted participants without any AMR were censored at the participant's last assessment or contact date collected in the study or at the analysis cut-off date, whichever was earlier.
No measurements were reported for this outcome.
Antibody mediated rejection was defined as the graft rejection due to generation of antibodies against the graft. The number of participants with AMR field checked as 'yes' based on the graft rejection biopsy in the electronic case report form was considered.
No measurements were reported for this outcome.
Number of participants with graft survival status as functioning at 6-months post-transplant was reported in this outcome measure.
| Participants | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With Calculated Panel Reactive Antibodies (cPRA) 80.00% to 99.89% |
|---|---|---|
| Number of Participants With Graft Survival at 6 Months Post-Transplant | 1 | 0 |
Collected over From first dose of study drug until study cut-off date (maximum duration: up to 97.7 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: Participants With cPRA >=99.90% | 1/12 (8.3%) | 0/12 (0%) | 3/12 (25%) |
| Cohort B: Participants With cPRA 80.00% to 99.89% | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Event | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% |
|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 2/12 | 3/11 |
| Covid-19Infections and infestations | 0/12 | 1/11 |
| NasopharyngitisInfections and infestations | 1/12 | 0/11 |
| HeadacheNervous system disorders | 1/12 | 0/11 |
| TachycardiaCardiac disorders | 1/12 | 0/11 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 1/12 | 0/11 |
| NauseaGastrointestinal disorders | 1/12 | 0/11 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/12 | 0/11 |
| Temporomandibular Joint SyndromeMusculoskeletal and connective tissue disorders | 1/12 | 0/11 |
| ChillsGeneral disorders | 1/12 | 0/11 |
Analysis was performed on all enrolled participants.
| Age, Continuous(years) | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% | Total |
|---|---|---|---|
| Mean | 49.7 ± 11.9 | 48.2 ± 12.3 | 49.0 ± 11.8 |
| Sex: Female, Male(Participants) | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% | Total |
|---|---|---|---|
| Female | 6 | 2 | 8 |
| Male | 6 | 9 | 15 |
| Race (NIH/OMB)(Participants) | Cohort A: Participants With cPRA >=99.90% | Cohort B: Participants With cPRA 80.00% to 99.89% | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 4 | 9 | 13 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jun 2020 to primary completion in May 2022, 22 months.
Results were first posted in May 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab